Amri

Berkshire Sterile Manufacturing Announces Tyne Jeffrey as the Vice President of Sales

Retrieved on: 
Thursday, August 5, 2021

The company announced the promotion of Tyne Jeffrey from the Director of Business Development to the Vice President of Sales.

Key Points: 
  • The company announced the promotion of Tyne Jeffrey from the Director of Business Development to the Vice President of Sales.
  • Tyne has over 18 years of experience in business development at several leading pharmaceutical manufacturing companies.
  • The Vice President of Sales is a key role in BSMs success as well as the success and satisfaction of its clients.
  • We are delighted to have her on our team, commented Berkshire Sterile Manufacturing cofounder and CEO, Dr. Shawn Kinney.

Curia Completes Acquisition of Integrity Bio

Retrieved on: 
Wednesday, August 4, 2021

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has completed the transaction to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California.

Key Points: 
  • Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has completed the transaction to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California.
  • We are excited to welcome our colleagues at Integrity Bio to Curia, bringing their deep scientific expertise and their dedication to improving patients lives, said Curia Chairman and CEO John Ratliff.
  • Our investment in this acquisition extends our global footprint and demonstrates our commitment to deepening our scientific know-how, particularly in biologics.
  • Integrity Bio will migrate to the Curia brand in the future.

AMRI Becomes Curia

Retrieved on: 
Monday, July 12, 2021

Albany Molecular Research, Inc. (AMRI), a leading global contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries, today announced that it is changing its name to Curia, effective July 12, 2021.

Key Points: 
  • Albany Molecular Research, Inc. (AMRI), a leading global contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries, today announced that it is changing its name to Curia, effective July 12, 2021.
  • View the full release here: https://www.businesswire.com/news/home/20210711005012/en/
    The name Curia is derived from a Latin word for purposeful assembly and references Curias patient-inspired mission.
  • Today, Curia offers a global suite of R&D and commercial manufacturing capabilities, with industry-leading expertise to help its customers accelerate the journey from idea to impact.
  • Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers.

AMRI Celebrates 30th Anniversary

Retrieved on: 
Tuesday, June 22, 2021

Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, celebrates 30 years since its incorporation in Albany, New York.

Key Points: 
  • Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, celebrates 30 years since its incorporation in Albany, New York.
  • Today, AMRI employs more than 3,100 people in 21 locations around the world, providing expert services from R&D through commercial manufacturing.
  • AMRI has 564 active patents and supports the production of more than 20 treatments included on the list of essential medicines from the World Health Organization.
  • AMRI , a contract research development and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life.

AMRI Adds to Accelerated R&D and Manufacturing Solutions for Orphan Products to Treat Rare Diseases

Retrieved on: 
Friday, April 30, 2021

b'Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced expanded access to its accelerated solutions platform, spanning research & development to manufacturing for orphan and rare disease products.

Key Points: 
  • b'Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced expanded access to its accelerated solutions platform, spanning research & development to manufacturing for orphan and rare disease products.
  • The products used to treat rare diseases are complex and innovative, addressing unmet needs using high-value drug substance.
  • Evaluate Pharma anticipates a 12% compound annual growth rate in prescription sales of orphan drugs from 2020 through 2026.
  • AMRI\xe2\x80\x99s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in discovery, development, analytical services, and API and drug product manufacturing.

AMRI Earns Spot on Forbes America’s Best Employers 2021 List

Retrieved on: 
Tuesday, March 9, 2021

Albany Molecular Research, Inc. ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced that the company is named on Americas Best Mid-Sized Employers 2021 list published by Forbes.

Key Points: 
  • Albany Molecular Research, Inc. ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced that the company is named on Americas Best Mid-Sized Employers 2021 list published by Forbes.
  • AMRI was included in the Drugs and Biotechnology industry category of the ranking.
  • Its 3,100 employees provide complex scientific solutions across the R&D and manufacturing continuum to pharmaceutical and biotechnology customers, helping improve patients lives.
  • Americas Best Employers 2021 is presented by Forbes and Statista Inc. Companies are selected through an independent survey applied to a sample of more than 50,000 American employees working for companies with more than 1,000 employees in America.

AMRI Joins Network of Approved Manufacturers of Lipid Excipients for Pfizer-BioNTech COVID-19 Vaccine

Retrieved on: 
Thursday, February 25, 2021

Albany Molecular Research, Inc. ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced that the company has been chosen to support the development and manufacture of lipid excipients for the Pfizer-BioNTech COVID-19 vaccine.

Key Points: 
  • Albany Molecular Research, Inc. ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced that the company has been chosen to support the development and manufacture of lipid excipients for the Pfizer-BioNTech COVID-19 vaccine.
  • This critical lipid excipient surrounds and protects the vaccines active ingredient.
  • Our response to this pandemic will continue to be both rapid and reliable, reflecting our dedication to quality delivery and scientific integrity.
  • AMRI , a contract research development and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life.

AMRI Appoints Scott Waldman to Lead Corporate Development

Retrieved on: 
Monday, February 8, 2021

Albany Molecular Research, Inc. ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced the appointment of Scott Waldman as senior vice president, corporate development, for AMRI.

Key Points: 
  • Albany Molecular Research, Inc. ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced the appointment of Scott Waldman as senior vice president, corporate development, for AMRI.
  • We are delighted to welcome Scott to the AMRI organization to lead this critical function, said John Ratliff , CEO, AMRI.
  • Waldman brings more than 25 years of experience to the role, in corporate development and as a general counsel and corporate lawyer, with more than 15 years focused on the pharmaceutical and pharmaceutical services industries.
  • AMRI , a contract research development and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life.

AMRI Wins 2021 CMO Leadership Awards

Retrieved on: 
Monday, February 1, 2021

Albany Molecular Research, Inc. ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced it has been recognized in the 2021 CMO Leadership Awards, presented by Outsourced Pharma and Life Science Leader.

Key Points: 
  • Albany Molecular Research, Inc. ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced it has been recognized in the 2021 CMO Leadership Awards, presented by Outsourced Pharma and Life Science Leader.
  • Recognition in the CMO Leadership Awards reflects the scientific expertise and passion for patients demonstrated by AMRI teams across the world, said John Ratliff , CEO, AMRI.
  • AMRI received six CMO Leadership Awards across all performance categories: capabilities, compatibility, expertise, quality, reliability and service based on small pharma respondents in primary market research conducted by Industry Standard Research (ISR).
  • Congratulations to all the 2021 CMO Leadership Award winners; you keep the biopharma industry moving forward.

Albany Molecular Research Inc. (AMRI) to Present at Jefferies 2020 Virtual London Healthcare Conference

Retrieved on: 
Wednesday, October 14, 2020

Albany Molecular Research, Inc., ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced that its CEO and CFO will present a corporate overview at the Jefferies 2020 Virtual London Healthcare Conference.

Key Points: 
  • Albany Molecular Research, Inc., ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced that its CEO and CFO will present a corporate overview at the Jefferies 2020 Virtual London Healthcare Conference.
  • The presentation, to be delivered by CEO John Ratliff and CFO Jason Knoblauch , will be recorded and made available on AMRIs website.
  • AMRIs executive team will also be available throughout the conference, November 17-19, 2020, to meet virtually with their industry peers to discuss ways AMRI can support their healthcare-focused efforts.
  • AMRI , a contract research development and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life.